Koh, Su-Jin http://orcid.org/0000-0002-1545-8036
Ohsumi, Shozo
Takahashi, Masato
Fukuma, Eisuke
Jung, Kyung Hae
Ishida, Takanori
Dai, Ming-Shen
Chang, Chuan-Hsun
Dalvi, Tapashi
Walker, Graham
Bennett, James
O’Shaughnessy, Joyce
Balmaña, Judith
Funding for this research was provided by:
AstraZeneca
Article History
Received: 25 March 2021
Accepted: 1 August 2021
First Online: 31 August 2021
Change Date: 25 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-021-01299-w
Declarations
:
: Shozo Ohsumi and Takanori Ishida have received honoraria for lecture fees from AstraZeneca. Kyung Hae Jung has received consultancy fees from AstraZeneca, Celgene, Eisai, Novartis, and Roche. Masato Takahashi has received honoraria for lecture fees from AstraZeneca, Eisai, Eli Lilly, and Pfizer. Tapashi Dalvi, Graham Walker, and James Bennett are employees or contracted employees of AstraZeneca and may own stock. Joyce O’Shaughnessy has received honoraria for consulting and advisory boards from AbbVie, Agendia, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Eli Lilly, Genentech, Genomic Health, GRAIL, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Seattle Genetics, and Syndax Pharmaceuticals. Judith Balmaña has received honoraria for consultancy from AstraZeneca, PharmaMar, and Pfizer, and research support from AstraZeneca and PharmaMar. Su-Jin Koh, Eisuke Fukuma, Ming-Shen Dai, and Chuan-Hsun Chang have nothing to declare.
: The study adhered to the Declaration of Helsinki, Good Clinical Practice, and Good Pharmacoepidemiology Practice, as well as relevant guidelines in each participating country. The study was approved by ethics committees/institutional review boards at all participating sites and it was registered on ClinicalTrials.gov (NCT03078036).
: Patients provided written informed consent for their medical records to be used in this study, blood sampling to assess g<i>BRCA</i> status (if unavailable in medical records), and tumor specimen testing in g<i>BRCA</i>-negative patients (if sufficient quality and quantity of archival sample was available).